

RECEIVED
CENTRAL FAX CENTER

JUN 30 2004

OFFICIAL

901 California Avenue Palo Alto, CA 94304-1104 Main: 650 • 496-6400 FAX: 650 • 496-1200

FAX TRANSMITTAL SHEET**NO. OF PAGES** (including this page): 7**TO:** Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**Attn:** Examiner
Art Unit: 1632
FAX: (703) 872-9306**FROM:** Sheela Mohan-Peterson
DATE: June 30, 2004**RE:** Docket No.: DX0670KB1B
USSN: 10/777,524
Filed: February 11, 2004
Title: Isolated Mammalian Monocyte Cell Genes; Related Reagents**Any difficulty with this facsimile, please call: Melanie Lyons at (650) 496-1183**

Documents attached:

- Transmittal (1 page)
- IDS and Form PTO/SB/08 (5 pages)

I hereby certify that this correspondence is being facsimile transmitted to the USPTO to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date
indicated below:

June 30, 2004
Melanie Lyons

CONFIDENTIALITY NOTE: This sheet and/or the document(s) accompanying it contain information belonging to DNAX which is confidential and/or legally privileged. The information is intended only for the use of the person or entity named above. If you have received this fax in error, please immediately notify us by telephone or return Fax.

PTO/SB/21 (03-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/777,524
		Filing Date	02/11/2004
		First Named Inventor	Gosse Jan ADEMA
		Art Unit	1632
		Examiner Name	
Total Number of Pages in This Submission	7	Attorney Docket Number	DX0670KB1B

ENCLOSURES (Check all that apply)


<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (2 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
Other Enclosures/Remarks: <ul style="list-style-type: none"> Form PTO/SB/08 (3 pages) Fax Transmittal Sheet (1 page) 		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual	Sheela Mohan-Peterson, Reg. No. 41,201 DNAX Research, Inc. 901 California Ave. Palo Alto, CA 94304-1104		
Signature			
Date	30-June-2004		

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this date indicated below:

Typed or printed	MELANIE LYONS		
Signature		Date	June 30, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

JUN 30 2004

OFFICIAL

Attorney Docket: DX0670KB1B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re application of:
Gosse Jan ADEMA, et al.

Examiner: Not yet assigned

Art Unit: 1632

Application No.: 10/777,524


Conf. No.: 8025

Filed: February 11, 2004

For: Isolated Mammalian Monocyte Cell
Genes; Related Reagents

I hereby certify that this correspondence is being facsimile
transmitted to the U.S. Patent and Trademark Office,
(703) 872-9306, Attn. Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450, on June 30, 2004

by:


MELANIE LYONS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

The materials as listed in the attached form PTO/SB/08 are brought to the Examiner's attention pursuant to the duty of disclosure under 37 C.F.R. § 1.56, § 1.97, and § 1.98. Attached please find Form PTO/SB08 listing references AA-AU.

All references listed on the attached form PTO/SB/08 have been previously cited either by Applicants or the Examiner in the following parent applications:

1. USSN 08/985,950, filed December 5, 1997, now US Patent No. 6,140,076;
2. USSN 09/546,049, filed April 10, 2000, now US Patent No. 6,479,638; and
3. USSN 10/290,631, filed November 8, 2002, currently pending.

Copies of the previously cited references should be available in these files. As such, these references will not be provided absent a specific request.

Citation of these documents should not be construed as a representation that the documents are in fact material or are in fact prior art with respect to the instant invention. The Examiner should not make any inference relating to the relative pertinence of cited references

based upon the order in which the art is presented. Citation of these documents should not be construed as a representation that a search has been made or that more pertinent art may not be in existence.

Applicants request that the Examiner fully consider the art cited in the attached PTO/SB/08 form. Applicants further request that the Patent and Trademark Office list all such art on the front of any patent issuing from this application.

Applicants believe no fee is required for filing this document; however, if such a fee is required the Commissioner is hereby authorized to charge DNAX Research Institute Deposit account no. 04-1239.

Respectfully submitted,

Date: 30 - June - 2004

By: Sheela Mohan-Peterson
Sheela Mohan-Peterson, Reg. No. 41,201
Attorney for Applicants

Customer No. 28008
DNAX Research, Inc.
901 California Avenue
Palo Alto, CA 94304-1104
Telephone (Switchboard): (650) 496-6400
Telephone No. (Direct): (650) 496-1244
Facsimile No.: (650) 496-1200

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known	
			Application Number	10/777,524
			Filing Date	February 11, 2004
			First Named Inventor	Gosse Jan ADEMA, et al.
			Art Unit	1632
			Examiner Name	Not yet assigned
			Attorney Docket Number	DX0670KB1B
Sheet	2	of	3	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AE	Mariana C. Castells, et al., <u>J. Biological Chemistry</u> , 269(11):8393-8401, 1994. "Cloning of the gp49B Gene of the Immunoglobulin Superfamily and Demonstration That One of Its Two Products Is an Early-expressed Mast Cell Surface Protein Originally Described as gp49 ⁴⁴ "	
	AF	Marco Colonna and Jacqueline Samaridis, <u>SCIENCE</u> , 268:405-408, April 21, 1998. "Cloning of Immunoglobulin-Superfamily Members Associated with HLA-C and HLA-B Recognition by Human Natural Killer Cells"	
	AG	M. Colonna and J. Samaridis, <u>GenBank</u> , Entrez Browser Protein Query, Accession Number 1171729, Database source: <u>Swiss-Prot</u> , Accession Number P43630, November 1, 1995. "Cloning of Immunoglobulin-Superfamily Members Associated with HLA-C and HLA-B Recognition by Human Natural Killer Cells"	
	AH	M. Colonna, et al., <u>Transplantation Proceedings</u> , 28(6):3035, December 1996. "Human Killer Inhibitory Receptors: Specificity for HLA-Class 1 Molecules and Mechanisms of Signal Transduction"	
	AI	L. Hillier, et al., <u>Gen Bank</u> , Accession No. H26010, July 10, 1995. "The WashU-Merck EST Project"	
	AJ	Dávid G. Jackson, et al., <u>Eur. J. Immunol.</u> , 22(5):1157-1163, 1992. "Molecular cloning of a novel member of the immunoglobulin gene superfamily homologous to the polymeric immunoglobulin receptor"	
	AK	Vladimír Korínek, et al., <u>Immunogenetics</u> , 33(2):108-112, February 1, 1991. "The human leukocyte antigen CD48 (MEM-102) is closely related to the activation marker Blast-1"	
	AL	Eric O. Long, et al., <u>Immunology Today</u> , 17(2):100, February 1996. "Inhibitory MHC class 1 receptors and T cells: a standard nomenclature"	
	AM	Charles R. Maliszewski, et al., <u>J. Exp. Med.</u> , 172:1665-1672, December 1990. "Expression Cloning of a Human Fc Receptor for IgA"	
	AN	Linde Meygaard, et al., <u>Immunity</u> , 7:283-290, August 1997. "LAIR-1, a Novel Inhibitory Receptor Expressed on Human Mononuclear Leukocytes"	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-785-9199) and select option 2.

